Triclosan: a First-of-its-Kind Biphenyl Compound to Increase the
Increases the efficacy of anthracycline therapy in cancer treatments. Reduces the cost of treating cancer patients due to more effective drugs used. Results in healthier cancer patients after treatment due to the reduced amount of metabolites causing cardiotoxicity.
Boise State University has developed a composition that reduces the negative permanent side effects of the chemotherapy drug anthracycline. It is anticipated that Triclosan may be administered along with anthracyclines as a cotherapy; or even pretreatment to block carbonyl reductase before administration. Most intriguing is the potential of triclosan in combination with one or more anthracycline compounds. This makes it attractive to companies developing improved formulations of adriamycin, daunomycin,daunorubicin, doxorubicin, epirubicin, and idarubicin.
Inventor: Charlier, Jr., Henry A. | Ewing, Christopher K.
Priority Number: US7781412B2
IPC Current: A01N004304 | A01N002700 | A01N002904 | A01N002910 | A61K0031015 | A61K0031025 | A61K003103 | A61K003170
US Class: 514034 | 514754 | 514755 | 514765
Assignee Applicant: Boise State University,Boise
Title: Biphenyl inhibitors of carbonyl reductase
Usefulness: Biphenyl inhibitors of carbonyl reductase
Summary: A pharmaceutical composition for preventing or reducing cardiotoxicity associated with anthracycline cancer chemotherapy (claimed).
Novelty: Pharmaceutical composition for preventing or reducing cardiotoxicity comprises anthracycline compound and enzyme inhibitor having two aryl groups connected with bridging atom, e.g. carbon, oxygen, sulfur, nitrogen, or their derivatives
診斷/治療
癌症/腫瘤
美國
